Combination antiretroviral chemotherapy: a potential strategy in AIDS-related malignancy.
There has been considerable interest and controversy over the potential clinical role of combination antiretroviral therapy, primarily in the treatment of patients with established HIV infection. In order to model the hematologic toxicity of high-dose combination antiretroviral therapy, the HL60 myeloid leukemia cell line was exposed to zidovudine, dideoxycytidine and/or didanosine. The results suggest that the myelotoxicity of high-dose combination antiretroviral therapy may be controlled by using very brief periods of drug exposure. Brief intense antiretroviral therapy may offer a useful approach, particularly in the treatment of patients with AIDS-related neoplasms who are also receiving myelotoxic antineoplastic drugs.
Nusbaum
N J
NJ
Lee Streich Flow Cytometry Laboratory, DWH Hematology/Oncology Complex, Brookdale Hospital Medical Center, Brooklyn, NY 11212 USA.
Abraham
T
T
D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D016049:Didanosine / Q000494:pharmacology; D015658:HIV Infections / Q000150:complications; D018922:HL-60 Cells / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D016047:Zalcitabine / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology
D000998:Antiviral Agents; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine